Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADC Therapeutics SAADCT · Entity 6502 | See Explanations | May 15, 2025 | May 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADC Therapeutics SA
Report date May 15, 2025 · Filed May 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 173,899 |
Reported balance
After 2025-05-15 transaction · row 1
1 source rowRow 1 · 2025-05-15 · Other · Disposed 451,856 · Balance 173,899 F1: In addition to the 173,899 shares still owned by Thomas Pfisterer, he previously held 451,856 shares directly or indirectly via HPWH MH AG ("MH") and HPWH TH AG ("HPWH") but following stepping down from the Board of Directors of MH and HPWH transferred ownership by way of an intragroup sale to Dr. Hans-Peter Wild. |
Filing footnotes · ownership attribution and instrument terms
F1: In addition to the 173,899 shares still owned by Thomas Pfisterer, he previously held 451,856 shares directly or indirectly via HPWH MH AG ("MH") and HPWH TH AG ("HPWH") but following stepping down from the Board of Directors of MH and HPWH transferred ownership by way of an intragroup sale to Dr. Hans-Peter Wild.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2025 Filed May 19, 2025 19:35 UTC | ADC Therapeutics SA ADCT · Entity 6502 | OtherCommon Shares | 451,856 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001731122-25-000777 · ownership.xml · nonDerivative · entry 1 Pfisterer Thomas · CIK 0001824238 · See Explanations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,899 F1 · kind: In addition to the 173,899 shares still owned by Thomas Pfisterer, he previously held 451,856 shares directly or indirectly via HPWH MH AG ("MH") and HPWH TH AG ("HPWH") but following stepping down from the Board of Directors of MH and HPWH transferred ownership by way of an intragroup sale to Dr. Hans-Peter Wild. F1 · price: In addition to the 173,899 shares still owned by Thomas Pfisterer, he previously held 451,856 shares directly or indirectly via HPWH MH AG ("MH") and HPWH TH AG ("HPWH") but following stepping down from the Board of Directors of MH and HPWH transferred ownership by way of an intragroup sale to Dr. Hans-Peter Wild. F1 · acquired: In addition to the 173,899 shares still owned by Thomas Pfisterer, he previously held 451,856 shares directly or indirectly via HPWH MH AG ("MH") and HPWH TH AG ("HPWH") but following stepping down from the Board of Directors of MH and HPWH transferred ownership by way of an intragroup sale to Dr. Hans-Peter Wild. Read SEC document |
| June 17, 2024 Filed Jun 19, 2024 01:38 UTC | ADC Therapeutics SA ADCT · Entity 6502 | SaleCommon Shares | 1,437 | $2.89 | $4,152.93 |
DisclosureSEC source: 0001628280-24-028989 · wk-form4_1718761112.xml · nonDerivative · entry 1 Pfisterer Thomas · CIK 0001824238 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,900 F1 · kind: Represents Common Shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 21:37 UTC | ADC Therapeutics SA ADCT · Entity 6502 | GrantCommon Shares | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-028351 · wk-form4_1718401022.xml · nonDerivative · entry 1 Pfisterer Thomas · CIK 0001824238 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,337 F1 · shares: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.